Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
Plus de filtres











Gamme d'année
1.
An. bras. dermatol ; An. bras. dermatol;93(6): 874-877, Nov.-Dec. 2018. tab, graf
Article de Anglais | LILACS | ID: biblio-973642

RÉSUMÉ

Abstract: Autoimmune progesterone dermatitis is an uncommon, poorly recognized and under-diagnosed catamenial dermatosis associated with hypersensitivity reactions to progestagens. Most cases manifest as urticaria, eczema or erythema multiforme-like. A 26-year-old woman developed violaceous plaques on the groin and abdomen, 4 days after a spontaneous abortion resolved with uterine curettage. The lesions recurred once monthly at the same sites, mimicking a fixed drug eruption. Although the histopathology was compatible with fixed drug eruption, positive intradermal testing and symptomatic improvement after using oral contraceptive pills gave us a clue to the diagnosis.


Sujet(s)
Humains , Femelle , Adulte , Progestérone/effets indésirables , Maladies auto-immunes/diagnostic , Toxidermies/diagnostic , Dermatite/diagnostic
2.
An Bras Dermatol ; 93(6): 874-877, 2018.
Article de Anglais | MEDLINE | ID: mdl-30484533

RÉSUMÉ

Autoimmune progesterone dermatitis is an uncommon, poorly recognized and under-diagnosed catamenial dermatosis associated with hypersensitivity reactions to progestagens. Most cases manifest as urticaria, eczema or erythema multiforme-like. A 26-year-old woman developed violaceous plaques on the groin and abdomen, 4 days after a spontaneous abortion resolved with uterine curettage. The lesions recurred once monthly at the same sites, mimicking a fixed drug eruption. Although the histopathology was compatible with fixed drug eruption, positive intradermal testing and symptomatic improvement after using oral contraceptive pills gave us a clue to the diagnosis.


Sujet(s)
Maladies auto-immunes/diagnostic , Dermatite/diagnostic , Toxidermies/diagnostic , Progestérone/effets indésirables , Adulte , Femelle , Humains
3.
Rev. méd. Chile ; 144(12): 1584-1590, dic. 2016.
Article de Espagnol | LILACS | ID: biblio-845489

RÉSUMÉ

Finasteride is a 5-α reductase inhibitor that is widely used in the management of benign prostate hyperplasia and male pattern hair loss. It is well known that these agents improve the quality of life in men suffering from these conditions. However, they are associated with some transient and even permanent adverse effects. The aim of this article is to clarify the controversies about the safety of finasteride by analyzing the evidence available in the literature.


Sujet(s)
Humains , Mâle , Finastéride/effets indésirables , Inhibiteurs de la 5-alpha réductase/effets indésirables , Hyperplasie de la prostate/traitement médicamenteux , Tumeurs de la prostate/prévention et contrôle , Spermatogenèse/effets des médicaments et des substances chimiques , Glycémie/métabolisme , Finastéride/usage thérapeutique , Alopécie/traitement médicamenteux , Métabolisme lipidique/effets des médicaments et des substances chimiques , Inhibiteurs de la 5-alpha réductase/usage thérapeutique , Dysfonctionnement érectile/induit chimiquement
4.
Rev Med Chil ; 144(12): 1584-1590, 2016 Dec.
Article de Espagnol | MEDLINE | ID: mdl-28393993

RÉSUMÉ

Finasteride is a 5-α reductase inhibitor that is widely used in the management of benign prostate hyperplasia and male pattern hair loss. It is well known that these agents improve the quality of life in men suffering from these conditions. However, they are associated with some transient and even permanent adverse effects. The aim of this article is to clarify the controversies about the safety of finasteride by analyzing the evidence available in the literature.


Sujet(s)
Inhibiteurs de la 5-alpha réductase/effets indésirables , Finastéride/effets indésirables , Inhibiteurs de la 5-alpha réductase/usage thérapeutique , Alopécie/traitement médicamenteux , Glycémie/métabolisme , Dysfonctionnement érectile/induit chimiquement , Finastéride/usage thérapeutique , Humains , Métabolisme lipidique/effets des médicaments et des substances chimiques , Mâle , Hyperplasie de la prostate/traitement médicamenteux , Tumeurs de la prostate/prévention et contrôle , Spermatogenèse/effets des médicaments et des substances chimiques
5.
Rev. méd. Chile ; 143(11): 1444-1448, nov. 2015.
Article de Espagnol | LILACS | ID: lil-771734

RÉSUMÉ

Ebola virus (EV) is one of the most virulent human pathogens. Fruits bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact. The actual outbreak started in December 2013 and crossed continental borders. Up to now, there are 17,145 suspected and confirmed cases with 6,070 deaths, resulting a total case fatality rate of 35%. Clinical manifestations can be divided in 3 phases. In phase I, symptoms are similar to flu, which may appear in a range of 2 to 21 days. In phase II which occurs in over 50% of cases, visceral symptoms and mucocutaneous manifestations appear within 4 and 5 days of the onset of symptoms. The main symptoms are a macular or maculopapular non-pruritic rash, desquamation and mucosal involvement of eyes, mouth and pharynx. In phase III, recovery or death occurs. The diagnosis is made on clinical grounds, epidemiological suspicion and a positive polymerase chain reaction (PCR) test. The treatment is supportive. If there is a suspected case, it should be notified immediately and all relevant safety measures should be instituted.


Sujet(s)
Animaux , Humains , Épidémies de maladies , Ebolavirus , Fièvre hémorragique à virus Ebola/épidémiologie , Fièvre hémorragique à virus Ebola/diagnostic , Fièvre hémorragique à virus Ebola/physiopathologie
6.
Rev Med Chil ; 143(11): 1444-8, 2015 Nov.
Article de Espagnol | MEDLINE | ID: mdl-26757869

RÉSUMÉ

Ebola virus (EV) is one of the most virulent human pathogens. Fruits bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact. The actual outbreak started in December 2013 and crossed continental borders. Up to now, there are 17,145 suspected and confirmed cases with 6,070 deaths, resulting a total case fatality rate of 35%. Clinical manifestations can be divided in 3 phases. In phase I, symptoms are similar to flu, which may appear in a range of 2 to 21 days. In phase II which occurs in over 50% of cases, visceral symptoms and mucocutaneous manifestations appear within 4 and 5 days of the onset of symptoms. The main symptoms are a macular or maculopapular non-pruritic rash, desquamation and mucosal involvement of eyes, mouth and pharynx. In phase III, recovery or death occurs. The diagnosis is made on clinical grounds, epidemiological suspicion and a positive polymerase chain reaction (PCR) test. The treatment is supportive. If there is a suspected case, it should be notified immediately and all relevant safety measures should be instituted.


Sujet(s)
Épidémies de maladies , Ebolavirus , Fièvre hémorragique à virus Ebola/épidémiologie , Animaux , Fièvre hémorragique à virus Ebola/diagnostic , Fièvre hémorragique à virus Ebola/physiopathologie , Humains
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE